Traumatic Brain Injury Market To Witness Growth at a CAGR of 5.54% for the Study Period 2018-2030 in the 7MM
- S&P 500, Dow climb for third day and close at records
- Tesla (TSLA) China Numbers 'Robust' - Wedbush
- Apple (AAPL) Shares Seen as 'Attractive' as Recent Checks Show Continuously Strong Demand - Citi
- Amazon.com warehouse workers vote to reject forming union in Alabama
- Traumatic Brain Injury Market size is expected to grow owing to the rise in investments by private players and a significant increase in R&D of novel therapeutic alternatives.
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
LAS VEGAS, Feb. 23, 2021 /PRNewswire/ -- DelveInsight's Traumatic Brain Injury (TBI) Market Report provides a comprehensive view of epidemiological trends, treatment approaches, unmet needs present in the TBI treatment market, and the pipeline therapies expected to impact the Traumatic Brain Injury market in the next decade in the 7MM (the US, EU5 (the UK, Germany, Spain, Italy, and France), and Japan).
The TBI market report lays forward the recent collaborations, deals, amongst companies, pharma companies accelerating the Traumatic Brain Injury market forward, along with ongoing clinical trials, and recent happenings in the TBI market landscape.
Some of the key highlights from the Traumatic Brain Injury Market Report:
- The current Traumatic Brain Injury Market treatment options include psychostimulants, antidepressants, antiparkinsonian agents, and anticonvulsants.
- The primary goal of Traumatic Brain Injury treatment is to prevent any secondary injury to the brain.
- Pipeline drugs such as VAS203 (Vasopharm), NeuroSTAT (NeuroVive Pharmaceutical), CEVA101 (Cellvaton), among others are being assessed as potential therapies to be available in the Traumatic Brain Injury market in the coming future.
- Expected launch of pipeline therapies with novel MoA is in 2024, 2025 and 2026
- Out of all the emerging therapies, VAS203, is expected to reach around $2.5B by 2030
- In 2019, NeuroSTAT received Fast Track designation from the FDA
For additional information on Market Impact by Therapies, visit Traumatic Brain Injury Market Insights
Traumatic Brain Injury is sudden damage to the brain, ranging from mild concussions to severe permanent brain damage, caused by a blow or jolt to the head. The common causes of injury can vary from car or motorcycle crashes, falls, sports injuries, and assaults.
Traumatic Brain Injury Epidemiology
The total 7MM incident cases of Traumatic Brain Injury were 4,053,203 in 2020, with males contributing more to the pool as compared to females.
DelveInsight's Traumatic Brain Injury Market Insights proffers a comprehensive outlay of the TBI epidemiology in the 7MM for the study period 2018-30 segmented into:
- Total Traumatic Brain Injury Incident cases
- Severity-specific cases of Traumatic Brain Injury
- Gender-specific cases Traumatic Brain Injury
- Traumatic Brain Injury Incidence Injury by Age Group
Know more about epidemiological trends @ Traumatic Brain Injury Prevalence
Traumatic Brain Injury Treatment Market
The Treatment modalities vary based on the severity of the injury. It ranges from daily cognitive therapy sessions to radical surgery such as bilateral decompressed craniotomies, and there exists guidelines for optimal TBI management, however, these cannot be used in every individual circumstance.
Current Traumatic Brain Injury treatment options comprise psychostimulants, antidepressants, antiparkinsonian agents, and anticonvulsants. These agents help in the management of neuropsychiatric, neurocognitive, and neurobehavioral sequelae of injury to the brain. Antidepressants such as citalopram, amitriptyline, paroxetine, sertraline, and others help in regulating the levels of the brain's natural chemical messengers. Anticonvulsant medications including sodium valproate, gabapentin, topiramate, and carbamazepine suppress the rapid and excessive firing of neurons that can lead to seizures. Anticonvulsants can also help in preventing the spread of a seizure within the brain and offer protection against possible. To manage pain, Pain management medications such as acetaminophen, ibuprofen, and naproxen sodium are used. To control the chemical balance and bodily movement, Motor system medications include baclofen, tizanidine, or cyclobenzaprine are prescribed.
Visit to know more present market outlook @ Traumatic Brain Injury Marketed Therapies
However, there is a lack of effective treatment for TBI recovery. Besides the lack of standard treatment approaches, the disease often gets misdiagnosed or underdiagnosed. There is a clear lack of clarity around the disease prognosis. A dearth of validation studies of outcome measured among particular sub-populations in which validity, reliability, and sensitivity have been assessed previously is another major setback that hinders the effective study of epidemiology, thus pathophysiology, and treatment approaches.
It is essential to develop tools that are sensitive to changes associated with treatment and rehabilitation regardless of TBI severity.
Pharma players Vasopharm, NeuroVive Pharmaceutical, BioVie, and several others are working to shift the dynamics of the Traumatic Brain Injury market landscape. The launch of emerging therapies is expected to boost the market size growth during the forecast period 2021–2030. Further, the TBI market size growth is anticipated to experience a rising trend in the cases owing to an increase in the number of head injuries. There is a significant increase in the R&D that is expected to augment the development of novel therapeutic alternatives in the global Traumatic Brain Injury market during the forecast period.
Traumatic Brain Injury Pipeline Therapies
- VAS203: Vasopharm
- NeuroSTAT: NeuroVive Pharmaceutical
- CEVA101: Cellvation
Know more about emerging therapies making an impact @ Traumatic Brain Injury Pipeline Therapies
Although, past decades have witnessed an increase in medical advancements, surgical interventions in the management of acute TBI patients. However, this has led to a surge in the population of TBI survivors which also implies an increased burden of TBI survivors with various disabilities has risen. Thus, there is a need for extensive pharmacokinetic evaluation of the potential neuroprotective agents in the injured brain to ensure adequate tissue penetration once the agent is studied in efficacy trials. Then, recent trends of treatment drop-outs have emerged as a major threat to the emerging TBI pipeline therapies.
To sum it all, for effective management of TBI patients, individualizing the treatment based on the patient's condition, and competency shall help in yielding better outcomes. An increase in the knowledge and awareness among the researchers shall further contribute to the Traumatic Brain Injury market revenue thereby offering immense opportunities for the key players in the market.
Contact for more insights @ TBI Market Landscape and Forecast
Scope of the Report
- Coverage: 7MM (The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan
- Study Period: 2018–2030
- TBI Market Segmentation: By Severity, Gender and age groups
- Key Companies: Vasopharm GmbH, Abliva and cellvation
- Key TBI Pipeline Therapies: VAS203, NeuroSTAT and CEVA101
- Analysis: Comparative and conjoint analysis of Traumatic Brain Injury Emerging therapies
- Tools used: SWOT analysis, Porter's Five Forces, PESTLE analysis, BCG Matrix
- analysis methods.
- Case Studies
- KOL's Views
- Analyst's Views
Table of Contents
Executive Summary of Traumatic Brain Injury
Competitive Intelligence Analysis for Traumatic Brain Injury
Traumatic Brain Injury: Market Overview at a Glance
Traumatic Brain Injury: Disease Background and Overview
Traumatic Brain Injury Epidemiology and Patient Population
Treatment Algorithm, Current Treatment, and Medical Practices
Key Endpoints of Traumatic Brain Injury Treatment
Traumatic Brain Injury: Seven Major Market Analysis
7MM: Market Outlook
Access and Reimbursement Overview of Traumatic Brain Injury
DelveInsight's "Brain Hemorrhage - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Brain Hemorrhage, historical and forecasted epidemiology as well as the Brain Hemorrhage market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
DelveInsight's 'Brain Implants Market Insights, Competitive Landscape and Market Forecast – 2025' report delivers an in-depth understanding of Brain Implants Market and the historical and forecasted Brain Implants Market trends in the US, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.
DelveInsight's 'Brain monitoring devices-Market Insights, Competitive Landscape and Market Forecast – 2025' report delivers an in-depth understanding of Brain monitoring devices and the historical and forecasted Brain monitoring devices market trends in the US, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.
DelveInsight's "Pediatric brain tumors Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Pediatric brain tumors, historical and forecasted epidemiology as well as the Pediatric brain tumors market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
DelveInsight's 'Deep Brain Stimulation Devices -Market Insights, Competitive Landscape and Market Forecast - 2025' report delivers an in-depth understanding of Deep Brain Stimulation Devices and the historical and forecasted Deep Brain Stimulation Devices market trends in the US, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.
DelveInsight's 'Traumatic Brain Injury - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted Traumatic Brain Injury epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
"Traumatic Brain Injury (TBI) Pipeline Insight, 2020" report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Traumatic Brain Injury market.
DelveInsight's 'Spinal Cord Injury–Market Insights, Epidemiology, and Market Forecast - 2030' report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology as well as the market trends of Spinal Cord Injury in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
DelveInsight's ' Chronic Spinal Cord Injury - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted Chronic Spinal Cord Injury epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
DelveInsight's 'Peripheral Nerve Injuries (PNI) - Market Insights, Epidemiology, and Market Forecast - 2030' report delivers an in-depth understanding of the PNI, historical and forecasted epidemiology as well as the PNI market trends in the United States, EU5(Germany, France, Italy, Spain, and the United Kingdom) and Japan.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
SOURCE DelveInsight Business Research, LLP
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Brandon Dawson Raises $250,000 For The Grant Cardone Foundation
- 24 CHILDREN FROM AROUND THE WORLD NAMED AS FINALISTS IN LIONS CLUBS INTERNATIONAL’S PEACE POSTER CONTEST
- BitMart Exchange Partners with MoonPay to Advance Fiat-to-Crypto Transaction